Table 1.
Demographics of participants and radioligand information of placebo and active cigarette scans
Figure 1.
Line plots of mean concentrations across subjects of nicotine in plasma versus time of active and placebo cigarette scans.
PET data acquisition began between 5 and 10 min on the time axis in individual subjects.
Table 2.
Concentrations of nicotine and metabolites in plasma during active and placebo cigarette scans.
Figure 2.
Positive correlation clusters of Δ[11C]carfentanil binding potential (BPND) (placebo - active) versus ΔVAS of feel the effect category in smokers, displayed on trans-axial images of a gray-matter probability maps.
Scatter plots of cluster Δ[11C]carfentanil BPND values to ΔVAS are shown together with regression lines. VAS stands for the visual analog scale of smoking effects, and R2 stands for the coefficient of determination of linear regression.
Table 3.
Clusters of Δ[11C]carfentanil BPND (placebo - active) to ΔVAS (active - placebo) correlation.
Figure 3.
Correlation clusters of [11C]carfentanil binding potential (BPND) of placebo-cigarette scans versus the Fagerström Test for Nicotine Dependence (FTND) in smokers, displayed on trans-axial images of a gray-matter probability maps.
Right panels show scatter plots using cluster [11C]carfentanil BPND, together with regression line. In regression equations, R2 stands for the coefficient of determination.
Table 4.
Clusters of placebo-cigarette [11C]carfentanil BPND to current nicotine-dependence and smoking statuses correlations in smokers.